An Integrated Microfluidic and Photonic Platform for Real-time Biomarker Quantification

用于实时生物标志物定量的集成微流控和光子平台

• 批准号: 566333-2021
• 负责人: Ban, DayanD
• 金额: $ 11.22万
• 依托单位: University of Waterloo
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=751508
• 关键词: Integrated; Microfluidic; Photonic; Platform; Real

Molecular detection has been widely used in clinical diagnostics to detect a molecule that is a biomarker of disease (or health risk) in a sample taken from a patient. It plays a critical role in disease control and pathogen monitoring, such as diabetes mellitus control, covid-19 pathogen tracking and cancer diagnosis. In Canada, about 3.0 million people were living with diagnosed diabetes in 2013-2014 and by 2022, about 2.2 million new cases of diabetes are expected. More than 1.2 million Canadian have contracted with covid-19 virus since early 2020 and more than 24 thousand died of it. In 2020, an estimated 225,800 Canadian are expected to be diagnosed with cancer. In order to address these pressing challenges to Canadian public health and well-beings, it is urgently needed to develop a technology that can be conveniently deployed at low costs to fast track and quantify disease-related biomarkers (i.e., molecules). However, existing molecular detection techniques have to be carried out typically in well-equipped central biomedical laboratories. We propose in this project one solution to miniaturize the molecular diagnostics, enabling point of care (POC) diagnostics where the test results can be obtained without relying complex biomedical or clinical lab facilities. The UWaterloo teams will work closely with the industry partner (AIH)., combine our complementary expertise and experience in micro-photonics, nanofabrication, microfluidics, molecular detection, artificial intelligence and life science, and develop a universal and miniaturized biosensor technology that can quantify the level of biomarkers of interest by measuring the intensity of fluorescently-labelled microbeads using a compact, low-cost microfluidic and photonic platform. Such a platform paves the way for widespread applications of POC to detect various types of analytes, such as glucose, insulin, infectious virus and cancer biomarkers. It can greatly facilitate disease control, enable more effective treatment of rapidly-progressing afflictions, and even make a life-or-death difference with highly mortality rate diseases such as the ongoing covid-19 pandemic. This project provides excellent HQP training in the fields of nanotechnology, life science and artificial intelligence.

分子检测已广泛应用于临床诊断，以检测从患者样本中提取的作为疾病（或健康风险）生物标志物的分子。它在疾病控制和病原体监测中发挥着关键作用，如糖尿病控制、covid-19病原体追踪和癌症诊断。在加拿大，2013-2014年约有300万人被诊断患有糖尿病，到2022年，预计将有220万新发糖尿病病例。自2020年初以来，超过120万加拿大人感染了covid-19病毒，超过2.4万人死于这种病毒。到2020年，预计将有225,800名加拿大人被诊断患有癌症。为了解决加拿大公共健康和福祉面临的这些紧迫挑战，迫切需要开发一种可以方便地以低成本部署的技术，以快速跟踪和量化与疾病相关的生物标志物（即分子）。然而，现有的分子检测技术通常必须在设备齐全的中央生物医学实验室中进行。在这个项目中，我们提出了一个解决方案，使分子诊断小型化，使护理点（POC）诊断能够在不依赖复杂的生物医学或临床实验室设施的情况下获得测试结果。滑铁卢大学团队将与行业合作伙伴（AIH）密切合作。，结合我们在微光子学，纳米制造，微流体，分子检测，人工智能和生命科学方面的互补专业知识和经验，开发一种通用和小型化的生物传感器技术，通过使用紧凑，低成本的微流体和光子平台测量荧光标记微珠的强度，可以量化感兴趣的生物标志物的水平。该平台为POC广泛应用于检测各种类型的分析物，如葡萄糖、胰岛素、感染性病毒和癌症生物标志物铺平了道路。它可以极大地促进疾病控制，更有效地治疗快速发展的疾病，甚至可以对高死亡率疾病（如正在进行的covid-19大流行）产生生死攸关的影响。该项目在纳米技术、生命科学和人工智能领域提供优秀的HQP培训。